[A25-143] Acalabrutinib (mantle cell lymphoma; combination with bendamustine and rituximab) – Addendum to Project A25-89
Last updated 18.12.2025
Project no.:
A25-143
Commission:
Commission awarded on 11.11.2025 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adults with previously untreated mantle cell lymphoma who are not eligible for autologous stem cell transplant
Result of dossier assessment:
- Patients for whom bendamustine + rituximab is a suitable individualized treatment: unchanged after addendum: hint of a lesser benefit
- Patients for whom bendamustine + rituximab is not a suitable individualized treatment: unchanged after addendum: added benefit not proven
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
DOI:
https://doi.org/10.60584/A25-143
| Project no. | Title | Status |
|---|---|---|
| A25-89 | Acalabrutinib (mantle cell lymphoma; combination with bendamustine and rituximab) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
18-12-2025 A G-BA decision was published.
G-BA documents on this decision